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25 years after HIV discovery: Prospects for cure and vaccine☆
Luc Montagnier
World Foundation AIDS Research and Prevention, UNESCO, Paris, FranceThe impressive advances of our scientiﬁc knowledge in the last
century allow us to have a much better vision of our origin on earth
and our situation in the Universe than our ancestors. Life has probably
started on Earth around 3 and half billion of years ago and a genetic
memory has early emerged, based on an extraordinary stable
molecule, the DNA double helix, bearing a genetic code identical for
all living organisms, from bacteria to men. We are thus the heirs of
myriads of molecular inventions which have accumulated over
millions–sometime billions–of years. The environmental pressure
has of course both maintained these inventions and also modulated
them over the generations, through death of the individuals and
sexual reproduction. For the last 30,000 years, our biological
constitution has not changed: a hypertrophic cortical brain, a larynx
to speak and a hand to manipulate. But for the last 10,000 years,
another memory has emerged, which makes our species quite
different from the others: this is the cultural memory which transmits
knowledge and societal organization from generation to next
generation, through the use of language, writing and more recently
virtual communication means.
This revolution occurred in several sites on the earth almost
simultaneously through sedentarization of human populations by
agriculture leading to several civilizations. Each human being thus
receives two luggages, the genetic memory at birth and cultural
memory during all his life and he will become a real human only if he
is beneﬁting of both. For the last 3 centuries, particularly in the 20th
century, our scientiﬁc knowledge has increased exponentially and has
diffused all over the world.
We have a tendency to consider ourselves as pure spirits, but the
hard reality still reminds us of our biological nature: each of us is
programmed to die and, during his life, is exposed to diseases. At the
dawnof this newcentury,weare still facing twomajorhealthproblems:
➢ New epidemics related to infectious agents (mostly bacteria and
viruses)
➢ Chronic diseases (mostly cancers, cardiovascular, neurodegener-
ative, arthritic, auto-immune diseases, diabetes) linked to the
increase of life expectancy and environmental changes related to
human activities.
This presentation will be obviously focused to one new epidemic,
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malaria and tuberculosis.
Moreover, other new epidemics should not be excluded as human
activities generate more favouring factors:
➢ Lack or loss of hygiene habits
➢ lack of water
➢ globalisation and acceleration of exchanges, travels
➢ atmospheric and chemical pollution leading to oxidative stress and
immune depression
➢ malnutrition, drug abuse, aging, also leading to immunedepression
➢ global warming leading to new ecological niches for insect vectors
➢ changes in sexual behaviours
This last factor and immune depression caused by malnutrition,
drug abuse and increased co-infections, are probably the causes of
emergence of AIDS as a global epidemic, affecting most if not all
continents including recently Polynesia islands.
The causative agent existed in Africa before the emergence of the
epidemics in Central Africa and North America in the 1970s. As there
exists related viruses apparently well tolerated in non-human
primates, it is tempting to consider AIDS as a zoonosis, resulting of
the transmission to human of related viruses infecting primate species
without causing disease.
But let us ﬁrst recall the circumstances of HIV discovery in my
laboratory at the Pasteur Institute (Fig. 1).
AIDS as a pathologic distinct entity was ﬁrst identiﬁed in June 1981
by members of the CDC (particularly James Curran) after reports
received from two medical doctors, Michael Gottlieb in Los Angeles
and Alvin Friedman-Kien in New York, of clusters of opportunistic
infections and Kaposi sarcoma occurring in young gay men which had
related sexual intercourse.
Following publication of this report in the CDC Bulletin, similar
cases were described in Western European countries and particularly
in France by a group of young clinicians and immunologists led by
Jacques Leibovitch and Willy Rozenbaum.
It was soon recognized that a similar disease, characterized at the
biological level by a profound depression of cellular immunity and
clinically by infections previously described in chemically or genet-
ically immunodepressed patients, also existed in haemophiliacs and
blood transfused patients.
The case of haemophiliacs was giving a clue as to the nature of the
transmissible agent: these AIDS patients had received puriﬁed
concentrates of factor 8 or 9, made from pools of blood donors
which had been ﬁltrated by bacteriological ﬁlters.
Fig. 1. The Pasteur team involved in the discovery of HIV in 1983–1984.
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compound and the ﬁltration should have retained bacterial or fungal
agents: only viruses could be present in the preparations given to
patients. This is why I become interested in a search for viruses; but
what kind of viruses? Many viruses have immunodepressing activity,
in order to persist in their hosts. This is particularly the case of herpes
viruses (cytomegalovirus) and retroviruses. A putative candidate was
the Human T Leukemia virus (HTLV) described by R.C. Gallo and
Japanese researchers.
Having more expertise on retroviruses (see biography Chapter I),
we embarked on the search for an HTLV-like virus, at the suggestion of
the French working group and also incited by the Institute Pasteur
Production, an industrial subsidiary of the Institute, producing an
hepatitis B vaccine from pool of plasmas from blood donors.
Knowing that retroviruses are usually expressed in activated cells,
I have set up classical conditions to grow in culture activated
lymphocytes, using ﬁrst a bacterial activator of both T and B
lymphocytes, Protein A, since I ignored in which subset of cells the
virus was hiding out.
The reasoning at that stage was that we should look ﬁrst in
lymphocytes from swollen lymph nodes, supposedly the site where
viruses accumulate in the early phase of infection.
I received in January 3 a biopsy of a patient with cervical
adenopathy, a symptom already recognized as an early sign of AIDS.
After dissection of the sample into small pieces and their dissociationFig. 2. HIV at the electron microscope.into single cells, the lymphocytes were cultured in nutrient medium
in the presence of Protein A and anti-interferon serum.
In fact, after addition of Interleukin 2, only T lymphocytes were
multiplying well and produced a small amount of virus detected by its
reverse transcriptase activity, measured by my associate Françoise
Barre-Sinoussi. Only some 9 months later could I show also growth of
the virus in B-lymphocytes transformed by Epstein–Barr virus
(Montagnier et al., 1984).
The viral growth ceased as the cellular growth started declining,
but we could propagate the virus in cultures of lymphocytes from
adult blood donors as well as in lymphocytes from chord blood. This
allowed characterization of the virus, and showed for the ﬁrst time
that it was different from HTLVs. A p24–25 protein could be
immuno-precipitated by the serum of the patient and not by
antibodies speciﬁc of the p24 gag protein of HTLV1, kindly provided
by Dr R.C. Gallo.
Electron microscopy of sections of the original lymph node biopsy,
as well as those from infected cultured lymphocytes, showed rare
viral particles with a dense conical core, similar to the retro-
lentiviruses of animals (infectious anaemia virus of horse, Visna
virus of sheep, etc.), but different from HTLV. Unlike the case of HTLV,
we could never see emergence of permanent transformed lines from
the infected lymphocyte cultures (Fig. 2).Fig. 3. Electron micrography picture of a giant cell (syncitium) resulting of the fusion of
many lymphocytes expressing the HIV fusion protein (Montagnier et al., 1984).
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(Barre-Sinoussi et al., 1983), together with two papers by Gallo and
Essex groups in favour of HTLV being the cause of AIDS. During the
following months, more data accumulated in my laboratory showing
that this new virus was not a passenger virus, but was really the best
candidate to be the cause of AIDS.
(1) The same type of virus was isolated from patients of different
origins: gay men with multiple partners, haemophiliacs, drug
abusers, Africans.
(2) Besides immune-precipitation of viral proteins (p25, P18),
serums from patients with lymphadenopathy syndrome and a
fraction of the serums from patients with advanced AIDS, were
positive in an ELISA test using proteins from partially puriﬁed
virus (Brun-Vezinet et al., 1984).
(3) In vitro, the viruswas shown to infect only CD4+T lymphocytes
and not the CD8+ subset (Klatzmann et al., 1984).
(4) A cytopathic effect was observed with isolates made from
patients with late symptoms of AIDS. Particularly the third
isolate made from a young gay man with Kaposi Sarcoma (Lai)Fig. 4. Genome structure of HIV1: gag, pol, env arecaused the formation of large syncitia, presumably due to the
fusion of several infected cells (Fig. 3). Attempts to grow the
ﬁrst isolate Bru in T cell lines isolated from patients with
leukaemia or lymphoma were unsuccessful. However, we
discovered later (Wain-Hobson et al., 1991) that the Bru isolate
was contaminated with the Lai isolate, which by contrast could
be grown in T cell lines (CEM, HUT78) in laboratories which
received our Bru isolate on their request.
In fact, a few laboratory isolates were shown to grow in mass
quantities in T cell lines, facilitating analysis of the virus and its use for
detection of antibodies by commercial blood tests.
Our data which I presented in September 1983 at a meeting on
HTLV in Cold Spring Harbor (Montagnier et al., 1984) were met with
skepticism and only in the Spring of 1984, the description of a quasi
identical virus under the name of HTLV III by the group of R.C. Gallo
(Popovicc et al., 1984) convinced the scientiﬁc community that this
new retrolentivirus was the cause of AIDS. The group of Jay Levy in San
Francisco also isolated the same kind of virus (Levy et al., 1984),
followed by many other laboratories.
However, a few opponents led by P. Duesberg argued and are still
arguing that there is no real demonstration that the virus does exist
and is the cause of AIDS according to Koch’s postulates.
In fact, the proviral DNA of the virus, renamed HIV (Human
Immunodeﬁciency Virus) by an international nomenclature Commit-
tee, was cloned and sequenced (Alizon et al., 1984; Wain-Hobson
et al., 1985; Ratner et al., 1985), showing the classical gene structure
of animal retroviruses which Dr Duesberg helped himself to uncover
at earlier times.
But in addition, new genes (Tat, Nef), important in regulation of
the expression of the viral genetic information, were recognized from
the DNA sequencing, making the viral genome probably the most
complex known in the retrovirus family (Fig. 4). HIV and its Primate
Cousins is therefore a well characterized entity only composed of DNA
sequences none existing in the human genome.
A posteriori, two facts should have provided to the few remaining
skeptics ﬁnal conviction that HIV is the culprit in AIDS:
(1) Transmission of AIDS by blood transfusion has practically
disappeared in countries where the detection of HIV antibodies
in blood donors has been implemented.the genes coding for the structural proteins.
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speciﬁc inhibitors of the viral enzymes (reverse transcriptase,
protease), has greatly improved the clinical conditions of the
patients. Mutations in the genome of HIV inducing resistance to
these inhibitors has led to relapses and aggravation of the
patients' condition.
In 1986, thanks to a collaboration with Portuguese colleagues, we
isolated a second virus (which I named HIV2), from West African
patients hospitalized in a Lisbon hospital (Clavel et al., 1986). They
all had the signs of AIDS but had no antibodies against our ﬁrst virus.
In fact, they had only antibodies to the most variable protein of HIV,
the surface glycoprotein. The patients had lost antibodies against the
well conserved internal proteins of HIV2 which show common
epitopes with their counterparts of HIV1, unlike the glycoprotein
(Fig. 5).
The isolation of HIV1 (Montagnier et al., 1984) and HIV2 (Clavel
et al., 1986) viruses from AIDS patients in Africa made us realize that
we were dealing with a large epidemic of heterosexually transmitted
viruses.
Evidence that HIV was not transmitted by casual contacts came
from our study in a French boarding school where HIV infected
haemophilic children were in close contact, day and night, with HIV
negative non-haemophilic children: none of the latter was found HIV
positive (Berthier et al., 1986).
The isolation of the virus causing AIDS allowed to implement
rational prevention measures and also to start a search for efﬁcient
viral inhibitors.
The ﬁrst candidate, azidothymidine, was an efﬁcient inhibitor of
HIV reverse transcriptase in in vitro experiments (Mitsuya). However,
its use in AIDS patients was soon recognized as disappointing
(Seligmann et al., 1994).
In fact, the treatment readily inducedmutants of the virus resistant
to AZT and did not extend the life span of the patients. The main
obstacle of treatment with a single or two inhibitors was the capacity
of the virus to mutate, which also impedes the design of an efﬁcient
vaccine and also explains the complexity of the pathophysiology of
AIDS.
Only a combination of three inhibitors proved to be efﬁcient on the
clinical outcome. Since 1996, clinicians are using HAART (Highly
Active Antiretroviral Therapy) to treat patients with high virus load
and low CD4+ T cell number, preventing then most of the time from
falling into lethal opportunistic infections (Zuniga et al., 2008).The HIV variability
In fact, in order to escape to the immune reactions of their hosts,
most viruses have a strategy to change their immunogenic epitopes.
In the case of HIV, a conjunction of several factors put it to an
unprecedented level.
I have listed below the factors which seem to be most responsible
for this variability.
(1) Errors of reverse transcription,
(2) Genetic recombination,
(3) Incomplete neutralization by Vif of the activity of the
APOBEC3G cellular gene,
(4) Oxidative stress.
The ﬁrst is that the replicative enzyme, reverse transcriptase (RT),
has no editing compensation, so that the transcription errors may
reach 1/105 nucleotides, far from 1/109 of the cellular DNA
polymerases.
However some other retroviruses, such as HTLV, do not show this
variation rate, since once integrated, the proviral DNA remains
replicated by the cellular DNA replicative machinery. The difference
could be explained by the fact that the HIV infected cells die, so that
the virus can maintain itself only by many cycles of new infections
involving each time reverse transcription of its RNA into DNA.
However, in in vitro infection of cell lines, also involving cytopathic
effect and many cycles of re-infection, the virus seems to be stable, in
the absence of immunoselective pressure.
Another factor of variation is genetic recombination. The immune
responses (humoral and cellular) against the virus are unable to
prevent a second virus infection of the host (because of virus
variability induced by the previous factor and other causes), so that
some cells could be co-infected by two viruses: this will also allow
genetic recombination between the two viral RNAs existing each in
two copies. The result is a “mosaic” virus in which many sequences
from the two original viruses are entangled, starting from “hot spots”
of recombination. This is particularly visible in Africa, probably
because of repeated exposure to infection of many patients. The
mosaic viruses, because of their selective advantage, then disseminate
in the infected population. The original subtypes called A B C D E G…
deﬁned by the sequence of their envelope gene are thus replaced by
A/G, B/C, etc… depending on the geographic location.
Moreover, two other factors have been more recently identiﬁed: In
the lymphocytes are expressed a family of genes coding for enzymes
Fig. 5. Immunoprecipitation of radio actively-labelled proteins of HIV1 and HIV2 by a
serum of an AIDS patient infected by HIV2; note in the HIV2 panel the precipitation of
the envelope protein.
Fig. 6. Evolution of HIV-1 infection in AIDS.
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viral genetic code (APOBEC3G). However, the virus has evolved a gene,
Vif, which can more or less counteract this effect, rendering viable the
viral DNAwithout completely avoidingmutations (Sheehy et al., 2002).
A last factor of variability, whose the importance has been
probably overlooked, is oxidative stress (see below), a cause of RNA
and DNA mutations (before integration of the proviral DNA): highly
reactive molecules derived from oxygen can oxidize the bases,
particularly guanine or deoxyguanine, thus modifying their coding
capacity or inducing a wrong replacement in repair.
A combination of these factors could explain both the intrinsic
variability of the virus in the host during the long evolution of
infection, and also the increasing variability of the circulating strains
as the epidemic is spreading in various populations.
We can at least act on this variability by decreasing the viral
multiplication rate inside the host by antiretroviral treatment and also
by neutralizing the oxidative stress.
The remaining problems:
How HIV infection results in the destruction of the immune
system
In early years following the virus discovery, it was generally
thought that the drop of CD4+ T cells was due to their direct infection
by a cytopathic virus.
In fact, the viral isolates (like Bru) made in the early stage of the
disease are not cytopathic, they use after binding to the CD4+
receptor of activated lymphocytes, a co-receptor (CCR5) which is the
receptor for a chemokine.
Only viruses isolated from patients at late stage of the disease are
cytopathic (like Lai) and their direct infection of the remaining T
lymphocytes (by using another chemokine co-receptor CXC4) could
account for the ﬁnal drop of these cells.
In fact, the number of activated CD4+ T lymphocytes (the ones
which only allow full replication of the virus), is probably a limiting
factor of the initial infection, after the ﬁrst contact with dendritic cells
and monocytes of genital or rectal mucosa. It is obvious that
inﬂammation and co-infections (bacterial, viral) could increase the
number of activated T lymphocytes and therefore could increase the
risk of HIV infection.
Recently, the virus has been found associated with the Peyer
patches existing around the small intestine which constitutes a major
source of activated T lymphocytes.
At the onset of infection, the virus replication is high in all the
lymphatic tissues, taking advantage of the delay of reaction of the
immune system (in time order, interferon, NK cells, CD8T cells,antibody response) and then decreases while persisting in some
lymph nodes (Fig. 6).
This is the beginning of the chronic phase which is generally
asymptomatic, although the lymphadenopathy is often present. It
has been shown that the virus replication continues in the lymph
nodes, despite the immune response. This one starts declining,
although there is a continuous renewal of T lymphocytes, both
CD4+ and CD8+, which could last for years.
During this period, we have found two phenomena which could
help explaining the indirect destruction of the immune system:
one biological: apoptosis
one biochemical: oxidative stress.
Apoptosis: my laboratory was the ﬁrst to describe this program
cell death in white blood cells cultured in medium deprived of
interleukin 2 (Gougeon et al., 1991). All the subsets, not only the
CD4+ T cells were affected when taken from the blood of
asymptomatic HIV patients as well as in patients presenting with
full blown AIDS: CD8+ T cells, NK cells, B lymphocytes, monocytes.
However, we found a good correlation between the drop of CD4+
T cells in patients and this in in vitro phenomenon (Gougeon et al.,
1993) We surmised that in the in vivo situation, cells were still alive
but in pre-apoptosis.
Indeed, we could detect in infected patients a general phenome-
non of immune activation (Gougeon et al., 1996), which has been now
well recognized as a major factor of AIDS pathogeny.
At the biochemical level, we also showed that the lymphocyte
population of asymptomatic patients (CD4+, CD8+, NK) displayed
the biochemical signs of oxidative stress (excess of free radicals
derived from oxygen): namely fast degradation of oxidized protein,
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In the patients' blood, we could detect similarly a hyper-oxidation of
plasma lipids (Lopez et al., 1996) and oxidization of guanine.
What could be the origin of this strong oxidative stress?At least one
HIV protein may contribute to it. It was shown by C. Flores, Mc Cord
and their collaborators that the Tat protein, among many functions,
inhibits the expression in lymphocytes of the Mn-dependent super-
oxide dismutase gene (Sevea et al., 1999). This enzyme is the key to
transform the anion superoxide, highly oxidant into hydrogen
peroxide. Tat has been shown to circulate in nanogram amounts in
the blood of infected patients and to penetrate inside cytoplasm.
In addition, bacterial and viral co-infectors can also induce
oxidative stress. We have been studying the possibility that a “cold”
persisting bacterial infection could co-exist in HIV infected patients.
These studies were initiated because we observed that in vitro co-
infection of lymphocytes with some mycoplasma species (M. pirum,
M. penetrans, M. fermentans) and HIV could greatly reinforce the
cytopathic effect of the latter.
Moreover, these small bacteria lack catalase, an enzyme able to
convert hydrogen peroxide into water. Therefore they also generate
oxidative stress and, furthermore, are activators of lymphocytes
(Sasaki et al., 1995).
In summary, the pathophysiology of AIDS is complex. HIV is the
main cause, but could also be helped by accomplices, and also have
some indirect effects by wrongly activating the immune system
through oxidative stress.
Prospects for the future
No cure. No vaccine, but maybe a cure by a vaccine
The advent of HAART has transformed AIDS in a tolerable infection,
but whatever the length of the treatment, the inhibitors used have not
reached the level of a cure! As soon as this treatment is interrupted,
virus multiplication resumes within a few weeks and the immune
system declines again.
This observation led researchers to think that there is a reservoir of
virus, to which the drugs have no access (Richman et al., 2009),
probably because the virus stays in a latent form in some tissues.
Our project is to design quantitative tests to evaluate the size of
this reservoir and to prevent it from giving rise to actively multiplyingFig. 7. CIRBA—Centre intégré de Recherchvirus by boosting the immune system against the most conserved
parts of viral proteins.
A schematic protocol of this therapeutic immunization, aimed at
achieving a functional eradication of HIV (Montagnier, 2007), could be
the following:
(1) First, antiretroviral therapy (HAART) for 3–6 months to reduce
viral load in the plasma to undetectable levels and maintain it
until the protocol has been terminated.
(2) Then, treat by antioxidants and immunostimulants such as an
orally absorbable form of glutathione to reduce the oxidative
stress induced by viral proteins and by HAART. Reduced
glutathione is known to induce a shift fromTh2 to TH1 responses,
therefore reinforcing cell-mediated immunity. Its effect can be
enhanced by some synthetic immunostimulants, which are now
close to approval for clinical use by regulatory authorities.
(3) After a 2-week treatment by the former products, start speciﬁc
immunization against HIV proteins by a therapeutic vaccine.
Trials with vaccine preparationmade for a therapeutic use have
already been carried out, with mixed results probably because
the immune system of the patients was not sufﬁciently
restored, or/and also due to the inadequacy of the immuno-
gens. Our data by genetic engineering indicate that the native
HIV glycoprotein must be modiﬁed in order to make immuno-
genic the most conserved parts of the protein, including the
pocket involved in HIV binding. This will result in a neutral-
ization capacity broad enough to cover potential escape
mutants. I advise also to add in the vaccine preparation two
other proteins involved in immuno-suppression, Tat and Nef,
also modiﬁed to become non-functional while remaining
immunogenic.
(4) After this vaccination, interrupt HAART. If the protocol has been
successful, there will be no virus rebound, as evidenced by a
low viral load and an increase of the CD4+ T cell component.
Regular monitoring of these two parameters will assess the
durability of the immunization. A strong cell-mediated immu-
nity, in addition to the induction of neutralizing antibodies, will
permit to interrupt a cycle of new cell infections by newly
formed viral particles. This control already exists spontaneous-
ly in a small number of HIV infected patients, which show no
immune depression even after many years.e Bioclinique d’Abidjan, créé en 1996.
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patient much more tolerable than a life-long antiretroviral therapy.
The protocol can also be applied to patients in early stages of HIV
infection, perhaps with a better chance of success, as their immune
system will have a better ability to respond.
If, in this optimistic scenario, HIV infection becomes a curable
disease, the impact on the epidemic itself will be considerable: in
developing countries, HIV infection represents a stigma for the
familial and professional life. Many infected individuals do not want
to be tested and to learn their status, and as consequence, they keep
transmitting the virus to new partners. The perspective of being
treated for a cure immediately after the diagnostic of HIV infection
will ease early testing and emergence of responsible behaviours.
Moreover, the success of a therapeutic vaccine will facilitate the
design of an efﬁcient preventive vaccine, based on the same viral
components.
Meanwhile, it will be essential to make accessible the use of
antiretroviral drugs to all patients who are eligible for it. This implies
not only an international effort to lower the price of the drugs, which
already has been partly achieved, but also a comparable effort to
create adequate medical structures with trained doctors and research
centres in developing countries. Our Foundation has chosen the
mission to contribute ﬁlling these tasks in Africa (Fig. 7).1
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